Date: 2015-10-05
Type of information: Resignation
Compound:
Company: Arena Pharmaceuticals (USA - CA)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On October 5, 2015, Arena Pharmaceuticals announced that, at the request of the Board of Directors, Jack Lief , Arena's President and Chief Executive Officer, has retired from the company, including its Board of Directors. Dr. Harry F. Hixson , a director of Arena since 2004, has been appointed to serve as interim Chief Executive Officer and interim principal financial officer. Arena will immediately initiate a search for a new chief executive officer.
Arena also reported that it is conducting an ongoing evaluation of its programs and operations, and intends to provide details regarding its 2016 financial plan later this year.
Dr. Hixson served as the Chairman of the board of directors of Sequenom, Inc., a genomics company, from January 2003 to March 2015 , and as its Chief Executive Officer from September 2009 to June 2014 . He previously served as Chief Executive Officer of BrainCells Inc. , a drug discovery and development company, from 2004 to 2005, as Chief Executive Officer of Elitra Pharmaceuticals Inc. , a biopharmaceutical company, from 1998 to 2003, and in various management positions with Amgen Inc., a biopharmaceutical company, from 1985 to 1991, most recently as President and Chief Operating Officer. Dr. Hixson holds a B.S. in Chemical Engineering from Purdue University , an M.B.A. from the University of Chicago and a Ph.D. in Physical Biochemistry from Purdue University .
Financial terms:
Latest news:
